Suppr超能文献

红核洗液治疗外阴阴道假丝酵母菌病有效性的系统评价和 Meta 分析。

Effectiveness of redcore lotion in patients with vulvovaginal candidiasis: a systematic review and Meta-analysis.

机构信息

Medical Research & Biometrics Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 102300.

出版信息

J Tradit Chin Med. 2022 Aug;42(4):487-492. doi: 10.19852/j.cnki.jtcm.2022.04.001.

Abstract

OBJECTIVE

To summarize and evaluate the effectiveness and safety of Redcore lotion on treating vulvovaginal candidiasis (VVC) using a systematic review and Meta-analysis of randomized controlled trials.

METHODS

A systematic literature search was performed in five English and three Chinese electronic databases up to October 2019. Randomized controlled trials in the treatment for VVC were included; only studies which compared the effectiveness and safety of Redcore lotion plus miconazole with miconazole alone were included. Relative risk (RR) and 95% confidence intervals (CI) were used in the Meta-analysis.

RESULTS

Seven studies involving 768 patients suffering from VVC were identified; 468 of the patients were pregnant women (60.9%). Combination group (Redcore lotion plus miconazole) was more effective in reduCIng symptomatic episodes of VVC than miconazole alone, with respect to cure rate (RR, 1.31; 95% CI, 1.09-1.57; P = 0.01), fungal culture negative rate (RR, 1.21; 95% CI, 1.04-1.41; P = 0.01), and effective rate (RR, 1.18; 95% CI, 1.05-1.35; P = 0.01). Subgroup analyses for pregnant women also showed that the combination group had superior outcomes with respect to VVC cure rate (RR, 1.48; 95% CI, 1.16-1.88, P < 0.01), fungal culture negative rate (RR, 1.26; 95% CI; 1.09-1.47; P < 0.01), and effective rate (RR, 1.25; 95% CI, 1.10-1.42; P < 0.01). Additionally, the observed risk of adverse events was lower in the combination medication group (RR, 0.30; 95% CI, 0.14-0.65; P < 0.01).

CONCLUSIONS

Though overall quality of individual studies was low, Redcore lotion plus miconazole can significantly improve clinical effectiveness and safety compared with miconazole alone.

摘要

目的

通过系统评价和 Meta 分析,总结和评估 Redcore 洗剂治疗外阴阴道念珠菌病(VVC)的有效性和安全性。

方法

系统检索了截至 2019 年 10 月的五个英文和三个中文电子数据库中的文献。纳入治疗 VVC 的随机对照试验;仅纳入比较 Redcore 洗剂联合咪康唑与咪康唑单独治疗有效性和安全性的研究。Meta 分析采用相对危险度(RR)和 95%置信区间(CI)。

结果

共纳入 7 项研究,涉及 768 例 VVC 患者,其中 468 例为孕妇(60.9%)。与咪康唑单独治疗相比,联合组(Redcore 洗剂联合咪康唑)在降低 VVC 症状发作方面更有效,治愈率(RR,1.31;95%CI,1.09-1.57;P=0.01)、真菌培养阴性率(RR,1.21;95%CI,1.04-1.41;P=0.01)和有效率(RR,1.18;95%CI,1.05-1.35;P=0.01)均较高。对于孕妇的亚组分析也显示,联合组在 VVC 治愈率(RR,1.48;95%CI,1.16-1.88,P<0.01)、真菌培养阴性率(RR,1.26;95%CI;1.09-1.47;P<0.01)和有效率(RR,1.25;95%CI,1.10-1.42;P<0.01)方面均有更好的结果。此外,联合用药组不良反应风险较低(RR,0.30;95%CI,0.14-0.65;P<0.01)。

结论

尽管个别研究的总体质量较低,但 Redcore 洗剂联合咪康唑与咪康唑单独治疗相比,能显著提高临床疗效和安全性。

相似文献

1
Effectiveness of redcore lotion in patients with vulvovaginal candidiasis: a systematic review and Meta-analysis.
J Tradit Chin Med. 2022 Aug;42(4):487-492. doi: 10.19852/j.cnki.jtcm.2022.04.001.
2
Probiotics for vulvovaginal candidiasis in non-pregnant women.
Cochrane Database Syst Rev. 2017 Nov 23;11(11):CD010496. doi: 10.1002/14651858.CD010496.pub2.
5
Miconazole-loaded nanoparticles coated with hyaluronic acid to treat vulvovaginal candidiasis.
Eur J Pharm Sci. 2023 Sep 1;188:106508. doi: 10.1016/j.ejps.2023.106508. Epub 2023 Jun 26.
6
Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection.
Cochrane Database Syst Rev. 2011 Aug 10(8):CD008739. doi: 10.1002/14651858.CD008739.pub2.
8
[Study on classification and treatment of vulvovaginal candidiasis].
Zhonghua Fu Chan Ke Za Zhi. 2005 Aug;40(8):532-5.
9
Treatment methods for vulvovaginal candidiasis in pregnancy.
J Mycol Med. 2021 Sep;31(3):101138. doi: 10.1016/j.mycmed.2021.101138. Epub 2021 May 7.

引用本文的文献

本文引用的文献

1
Candida africana vulvovaginitis: Prevalence and geographical distribution.
J Mycol Med. 2020 Sep;30(3):100966. doi: 10.1016/j.mycmed.2020.100966. Epub 2020 Apr 5.
4
Efficacy of antifungal drugs in the treatment of vulvovaginal candidiasis: a Bayesian network meta-analysis.
Infect Drug Resist. 2018 Oct 17;11:1893-1901. doi: 10.2147/IDR.S175588. eCollection 2018.
5
Global burden of recurrent vulvovaginal candidiasis: a systematic review.
Lancet Infect Dis. 2018 Nov;18(11):e339-e347. doi: 10.1016/S1473-3099(18)30103-8. Epub 2018 Aug 2.
6
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species.
Expert Opin Pharmacother. 2018 Jun;19(9):971-977. doi: 10.1080/14656566.2018.1476490. Epub 2018 Jun 22.
7
Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines.
Clin Infect Dis. 2015 Dec 15;61 Suppl 8:S759-62. doi: 10.1093/cid/civ771.
8
Medically important fungi respond to azole drugs: an update.
Future Microbiol. 2015;10(8):1355-73. doi: 10.2217/FMB.15.47. Epub 2015 Aug 3.
9
Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis.
J Obstet Gynaecol Can. 2015 Mar;37(3):266-274. doi: 10.1016/S1701-2163(15)30316-9.
10
Vulvovaginal candidiasis in pregnancy.
Curr Infect Dis Rep. 2015 Jun;17(6):462. doi: 10.1007/s11908-015-0462-0.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验